跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
Yi Ping Hung
, Yu Yun Shao
, Jan Mou Lee
, Chiun Hsu
, Chih Hung Hsu
,
Muh Hwa Yang
*
, Yee Chao
*
此作品的通信作者
臨床醫學研究所
研究成果
:
Article
›
同行評審
15
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Biological Marker
100%
Hepatocellular Carcinoma
100%
Combination Therapy
100%
Immunocompetent Cell
100%
Nivolumab
100%
Diseases
100%
Programmed Death 1 Ligand 1
80%
Disease Exacerbation
60%
B Cell
40%
Flow Cytometry
20%
Immunotherapy
20%
Clinical Trial
20%
Cytotoxic T-Cell
20%
T Cell
20%
T-Helper Cell
20%
Advanced Cancer
20%
Lymphocyte
20%
Keyphrases
Treatment Efficacy
100%
Programmed Death-ligand 1 (PD-L1)
100%
Advanced Hepatocellular Carcinoma
100%
Circulating Immune Cells
100%
Nivolumab
100%
Disease Progression
37%
Disease Control
37%
Monocytes
25%
Non-associated
25%
Peripheral B Cells
25%
Treatment Outcome
25%
Flow Cytometry
12%
Clinical Trials
12%
T Cells
12%
CD8+ T Cells
12%
Lymphocytes
12%
Partial Response
12%
Peripheral Blood
12%
Immune Cells
12%
Complete Response
12%
Stable Disease
12%
Advanced Cancer
12%
Objective Response Rate
12%
Disease Control Rate
12%
Days of Treatment
12%
Hemogram
12%
CD4 T Cells
12%
Anti-programmed death-1 Monoclonal Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Combination Therapy
100%
Biological Marker
100%
Nivolumab
100%
Diseases
100%
Programmed Death 1 Ligand 1
80%
Disease Exacerbation
60%
Immunotherapy
20%
Clinical Trial
20%
CD8 Antigen
20%
Flow Cytometry
20%
Advanced Cancer
20%
Immunology and Microbiology
Immunocompetent Cell
100%
Programmed Death 1 Ligand 1
100%
Nivolumab
100%
B Cell
50%
Immunotherapy
25%
Cytotoxic T-Cell
25%
T Cell
25%
T-Helper Cell
25%
Lymphocyte
25%